IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$37.59
+0.37%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.3x
Market Cap
$3.63B
MomentumView details →
1D Return
+0.37%
YTD Return
+8.52%
RSI (14)
43.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.3x
Market Cap
$3.63B
RSI (14)
43.1
MomentumView details →
1D Return
+0.37%
YTD Return
+8.52%
SummaryUpdated Jun 1, 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company founded in 2015 and headquartered in South San Francisco, California. The company went public in May 2019 and focuses on developing targeted cancer therapeutics using a synthetic lethality approach. IDEAYA identifies specific genetic vulnerabilities in cancer cells and develops drugs that exploit these weaknesses while sparing healthy cells. The company currently has multiple drug candidates in clinical trials and maintains strategic partnerships with major pharmaceutical companies including Pfizer and GlaxoSmithKline.
Similar companies
Latest newsMore news →
IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.24d agoIDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.39d ago